scholarly journals Clinical characteristics and antimicrobial resistance of pneumococcal isolates of pediatric invasive pneumococcal disease in China

2018 ◽  
Vol Volume 11 ◽  
pp. 2461-2469 ◽  
Author(s):  
Kang Cai ◽  
Yizhong Wang ◽  
Zhongqin Guo ◽  
Xiaonan Xu ◽  
Huajun Li ◽  
...  
2021 ◽  
Vol 9 (7) ◽  
pp. 1428
Author(s):  
Catarina Silva-Costa ◽  
Joana Gomes-Silva ◽  
Lúcia Prados ◽  
Mário Ramirez ◽  
José Melo-Cristino ◽  
...  

The introduction of pneumococcal conjugate vaccines PCV7 and PCV13 led to decreases in incidence of pediatric invasive pneumococcal disease (pIPD) and changes in serotype distribution. We evaluated the consequences of higher vaccine uptake after the introduction of PCV13 in the National Immunization Plan (NIP) in 2015. Besides culture and conventional serotyping, the use of molecular methods to detect and serotype pneumococci in both pleural and cerebrospinal fluid samples contributed to 30% of all pIPD (n = 232) in 2015–2018. The most frequently detected serotypes were: 3 (n = 59, 26%), 10A (n = 17, 8%), 8 (n = 16, 7%) and 19A (n = 10, 4%). PCV13 serotypes still accounted for 46% of pIPD cases. Serotypes not included in any currently available conjugate vaccine (NVT) are becoming important causes of pIPD, with the increases in serotypes 8 and 33F being of particular concern given the importance of serotype 8 in adult IPD and the antimicrobial resistance of serotype 33F isolates. This study highlights the importance of using molecular methods in pIPD surveillance since these allowed a better case ascertainment and the identification of serotype 3 as the leading cause of pIPD. Even in a situation of vaccine uptake >95% for 3 years, PCV13 serotypes remain important causes of pIPD.


2001 ◽  
Vol 20 (5) ◽  
pp. 0299-0308 ◽  
Author(s):  
H. Laurichesse ◽  
J. P. Romaszko ◽  
L. T. Nguyen ◽  
B. Souweine ◽  
V. Poirier ◽  
...  

2011 ◽  
Vol 22 (4) ◽  
pp. 137-141 ◽  
Author(s):  
Jennie Johnstone ◽  
Gregory J. Tyrrell ◽  
Thomas J. Marrie ◽  
Sipi Garg ◽  
James D. Kellner ◽  
...  

The objective of this study was to describe the epidemiology, clinical characteristics, microbiology and outcomes of patients of all ages withStreptococcus pneumoniaemeningitis between 2000 and 2004; two years pre- and postintroduction of anS pneumoniae7-valent conjugate vaccine program in Alberta in children younger than two years of age. The high mortality rate associated withS pneumoniaemeningitis, despite appropriate therapy, suggests that prevention ofS pneumoniaemeningitis is critical. Despite implementation of a PCV-7 program in Alberta, rates ofS pneumoniaemeningitis in children younger than two years of age is still high. Thus, continued research into safe and efficacious vaccines covering a broader range ofS pneumoniaeserotypes is necessary.OBJECTIVE: To describe the epidemiology, clinical characteristics, microbiology and outcomes of patients of all ages withStreptococcus pneumoniaemeningitis two years pre- and postintroduction of aS pneumoniae7-valent conjugate vaccine program in Alberta in children <2 years of age.METHODS: Between 2000 and 2004, all cases of invasive pneumococcal disease in Alberta were identified. From this cohort, patients withS pneumoniaemeningitis were identified by chart review. Clinical data, laboratory data and in-hospital outcomes were collected.RESULTS: Of the 1768 cases of invasive pneumococcal disease identified between 2000 and 2004, 110 (6.2%) hadS pneumoniaemeningitis. The overall incidence was 0.7 per 100,000 persons and remained unchanged over the study period. The rate in children <2 years of age appeared to fall over time, from 10.5 per 100,000 persons in 2000 to five per 100,000 persons in 2004, although there was insufficient evidence of a statistically significant time trend within any age group. Overall, the mean age was 30 years and 47% were male. In-hospital mortality was 20%, ranging from 6% in those ≤2 years of age to 31% for those ≥18 years of age, despite appropriate antimicrobial therapy.CONCLUSION: The high mortality rate associated withS pneumoniaemeningitis suggests that prevention by vaccination is critical. In children <2 years of age, there was a downward trend in the rate ofS pneumoniaemeningitis after implementation of theS pneumoniae7-valent conjugate vaccine program, but rates were still high.


2002 ◽  
Vol 35 (4) ◽  
pp. 420-427 ◽  
Author(s):  
Julia Y. Morita ◽  
Elizabeth R. Zell ◽  
Richard Danila ◽  
Monica M. Farley ◽  
James Hadler ◽  
...  

2020 ◽  
Vol 71 (8) ◽  
pp. e235-e243 ◽  
Author(s):  
Zahin Amin-Chowdhury ◽  
Sarah Collins ◽  
Carmen Sheppard ◽  
David Litt ◽  
Norman K Fry ◽  
...  

Abstract Background England is experiencing a rapid increase in invasive pneumococcal disease (IPD) caused by serotypes 8, 12F, and 9N; their clinical characteristics and outcomes have not been described. Methods Public Health England conducts national IPD surveillance. Cases due to emerging serotypes were compared with those included in the 13-valent pneumococcal conjugate vaccine (PCV13) and the remaining non-PCV13 serotypes. Results There were 21 592 IPD cases during 2014–15 to 2017–18, including 20 108 (93.1%) with serotyped isolates and 17 450 (86.8%) with completed questionnaires. PCV13 serotypes were responsible for 20.1% (n = 4033), while serotype 8 (3881/20 108 [19.3%]), 12F (2365/20 108 [11.8%]), and 9N (1 296/20 108 [6.4%]) were together responsible for 37.5% of cases. Invasive pneumonia was the most common presentation (11 424/16 346 [69.9%]) and, overall, 67.0% (n = 11 033) had an underlying comorbidity. The median age (interquartile range) at IPD due to serotypes 8 (59 [45–72] years) and 12F (56 [41–70] years) was lower than serotype 9N (67 [53–80] years), PCV13 serotypes (68 [52–81] years), and remaining non-PCV13 serotypes (70 [53–82] years). Serotype 9N IPD cases also had higher comorbidity prevalence (748/1087 [68.8%]) compared to serotype 8 (1901/3228 [58.9%]) or 12F (1042/1994 [52.3%]), and higher case fatality (212/1128 [18.8%]) compared to 8.6% (291/3365) or 10.0% (209/2086), respectively. Conclusions Serotypes 8 and 12F were more likely to cause IPD in younger, healthier individuals and less likely to be fatal, while serotype 9N affected older adults with comorbidities and had higher case fatality.


2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Paula O. Narváez ◽  
Salome Gomez-Duque ◽  
Juan E. Alarcon ◽  
Paula C. Ramirez-Valbuena ◽  
Cristian C. Serrano-Mayorga ◽  
...  

Abstract Background The incidence of invasive pneumococcal disease (IPD) varies depending on a number of factors, including vaccine uptake, in both children and adults, the geographic location, and local serotype prevalence. There are limited data about the burden of Streptococcus pneumoniae (Spn), serotype distribution, and clinical characteristics of adults hospitalized due to IPD in Colombia. The objectives of this study included assessment of Spn serotype distribution, clinical characteristics, mortality, ICU admission, and the need for mechanical ventilation. Methods This was an observational, retrospective, a citywide study conducted between 2012 and 2019 in Bogotá, Colombia. We analyzed reported positive cases of IPD from 55 hospitals in a governmental pneumococcal surveillance program. Pneumococcal strains were isolated in each hospital and typified in a centralized laboratory. This is a descriptive study stratified by age and subtypes of IPD obtained through the analysis of medical records. Results A total of 310 patients with IPD were included, of whom 45.5% were female. The leading cause of IPD was pneumonia (60%, 186/310), followed by meningitis. The most frequent serotypes isolated were 19A (13.87%, 43/310) and 3 (11.94%, 37/310). The overall hospital mortality rate was 30.3% (94/310). Moreover, 52.6% (163/310 patients) were admitted to the ICU, 45.5% (141/310) required invasive mechanical ventilation and 5.1% (16/310) non-invasive mechanical ventilation. Conclusion Pneumococcal pneumonia is the most prevalent cause of IPD, with serotypes 19A and 3 being the leading cause of IPD in Colombian adults. Mortality due to IPD in adults continues to be very high.


Sign in / Sign up

Export Citation Format

Share Document